Hypoxia-specific therapeutic agents delivery nanotheranostics: A sequential strategy for ultrasound mediated on-demand tritherapies and imaging of cancer

Feng, Qianhua; Li, Yuzhen; Yang, Xuemei; Zhang, Wanxia; Hao, Yongwei; Zhang, Hongling; Hou, Lin; Zhang, Zhenzhong

doi:10.1016/j.jconrel.2018.02.011

Cited by 104 publications

(65 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sonodynamic therapy (SDT), which is based on ultrasound (US)‐triggered sonosensitizers that produce reactive oxygen species (ROS), obviates the above limitation of photodynamic therapy (PDT), and is a suitable option for treating deep‐seated tumors . In addition to oxidative damage, SDT also causes irreversible damage to tumor cells by cavitation independent of sonosensitizers . Furthermore, the specificity of SDT to the targeted lesions minimize damage of the normal tissues by the chemotherapeutic drugs or high intensity focused US .…”

Section: Introductionmentioning

confidence: 99%

ROS‐Responsive Blended Nanoparticles: Cascade‐Amplifying Synergistic Effects of Sonochemotherapy with On‐demand Boosted Drug Release During SDT Process

Dong

Guo

et al. 2019

Adv Healthcare Materials

View full text Add to dashboard Cite

Sonodynamic therapy (SDT) not only has greater tissue‐penetrating depth compared to photo‐stimulated therapies, but also can also trigger rapid drug release to achieve synergistic sonochemotherapy. Here, reactive oxygen species (ROS)‐responsive IR780/PTL‐ nanoparticles (NPs) are designed by self‐assembly, which contain ROS‐cleavable thioketal linkers (TL) to promote paclitaxel (PTX) release during SDT. Under ultrasound (US) stimulation, IR780/PTL‐NPs produce high amounts of ROS, which not only induces apoptosis in human glioma (U87) cells but also boosts PTX released by decomposing the ROS‐sensitive TL. In the U87 tumor‐bearing mouse model, the IR780/PTL‐NPs releases the drug at the target sites in a controlled manner upon US irradiation, which significantly inhibits tumor growth and induces apoptosis in the tumor tissues with no obvious toxicity. Taken together, the IR780/PTL‐NPs are a novel platform for sonochemotherapy, and can control the spatio‐temporal release of chemotherapeutic drugs during SDT.

show abstract

Section: Introductionmentioning

confidence: 99%

ROS‐Responsive Blended Nanoparticles: Cascade‐Amplifying Synergistic Effects of Sonochemotherapy with On‐demand Boosted Drug Release During SDT Process

Dong

Guo

et al. 2019

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Cytotoxic reactive oxygen species (ROS) can be produced when the oxygen and sonosensitizer are activated by ultrasound (US). Unfortunately, the hypoxic environment in ovarian cancer is the major cause of treatment failure, and SDT would aggravate tumor hypoxia phenomenon due to the consumption of oxygen . Therefore, the key is how to improve the therapeutic efficiency of SDT under the hypoxic environment.…”

Section: Introductionmentioning

confidence: 99%

A Core–Shell Nanoplatform for Synergistic Enhanced Sonodynamic Therapy of Hypoxic Tumor via Cascaded Strategy

Wang

Niu

Zheng

et al. 2018

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Sonodynamic therapy (SDT) always causes tumor hypoxia aggravation which can induce malignant cell proliferation and drug resistance. To overcome these disadvantages, a cascaded drug delivery system (Lipo/HMME/ACF@MnO2‐AS1411) is constructed for synergistic enhanced sonodynamic therapy. First, hematoporphyrin monomethyl ether (HMME) and acriflavine (ACF) are encapsulated in the lipid layers and the inner aqueous cores of the liposomes, respectively. Then the ultrathin manganese dioxide (MnO2) nanosheets are coated on the surface of the liposomes by using KMnO4 and polyethylene glycol through “one step reduction and modification” method. Furthermore, the nanoparticles are decorated with tumor‐targeting AS1411 aptamer through the phosphate groups on the DNA strand which can bind to Mn sites to obtain Lipo/HMME/ACF@MnO2‐AS1411 delivery system. Herein, HMME can act as a sonosensitizer, and ACF is used to prevent the formation of HIF‐1α/HIF‐1β dimerization to overcome the negative effects after SDT. The Lipo/HMME/ACF@MnO2‐AS1411 delivery system has multiple functions, including codelivery of HMME and ACF, pH/glutathione/ultrasound triple responses, synergistic cascaded enhancement of SDT, precise tumor‐targeting, and magnetic resonance imaging. The in vitro and in vivo results suggest that the Lipo/HMME/ACF@MnO2‐AS1411 delivery system is a promising core–shell nanoplatform for synergistic enhancement of sonodynamic therapy, which can provide a new approach in the related research fields.

show abstract

“…We further examined whether the autonomous NPs generator could facilitate drugs efficiently targeting to the tumor tissues in vivo, the real‐time NIR fluorescence distribution was monitored by IR780‐labeled formulations . As shown in Figure A, the IR780/Spore‐DA group exhibited a strong fluorescence signal in tumor site at 10 h and remained obviously fluorescence until 4 8 h; however, the other groups displayed almost negligible fluorescence signal, indicating that more IR780/Spore‐DA was delivery to the tumor site.…”

Section: Methodsmentioning

confidence: 99%

A Probiotic Spore‐Based Oral Autonomous Nanoparticles Generator for Cancer Therapy

Song¹,

Zheng²,

Jia³

et al. 2019

Advanced Materials

Self Cite

View full text Add to dashboard Cite

Spores, the dormant life forms of probiotics, can germinate to metabolically active vegetative cells with the disintegration of their hydrophobic protein coat in the intestinal microenvironment, which provides the possibility for the formation of nanoparticles (NPs) in vivo. Inspired by the natural physiological process of spores, herein, an oral autonomous NPs generator is developed to overcome the spatially variable gastrointestinal tract environment and multibiological barriers. Spores modified with deoxycholic acid (DA) and loaded with chemotherapeutic drugs (doxorubicin and sorafenib, DOX/SOR) serve as an autonomous production line of NPs, which can efficaciously protect the drugs passing through the rugged environment of the stomach and furthermore can be transported to the intestinal environment and colonized rapidly. Subsequently, the DOX/SOR/Spore‐DA NPs are produced by the autonomous NPs generator in the intestinal regions based on the disintegrated hydrophobic protein and the hydrophilic DA, and they can efficiently penetrate the epithelial cells via the bile acid pathway, increasing basolateral drug release. In vitro and in vivo studies confirm that this biological nanogenerator can autonomously produce substantial NPs in the intestine, providing a promising strategy for cancer therapy.

show abstract

Hypoxia-specific therapeutic agents delivery nanotheranostics: A sequential strategy for ultrasound mediated on-demand tritherapies and imaging of cancer

Cited by 104 publications

References 36 publications

ROS‐Responsive Blended Nanoparticles: Cascade‐Amplifying Synergistic Effects of Sonochemotherapy with On‐demand Boosted Drug Release During SDT Process

ROS‐Responsive Blended Nanoparticles: Cascade‐Amplifying Synergistic Effects of Sonochemotherapy with On‐demand Boosted Drug Release During SDT Process

A Core–Shell Nanoplatform for Synergistic Enhanced Sonodynamic Therapy of Hypoxic Tumor via Cascaded Strategy

A Probiotic Spore‐Based Oral Autonomous Nanoparticles Generator for Cancer Therapy

Contact Info

Product

Resources

About